Paul Brian Fisher, 52Jeffersonville, IN

6355622, Mar 12, 2002

Feb 16, 1999

09/251124

Paul B. Fisher - Scarsdale NY

The Trustees of Columbia University in the City of New York - New York NY

A01N 4304

514 44, 435 6, 435 691

This invention provides a method for reversing the cancerous phenotype of a cancer cell by introducing a nucleic acid having the melanoma differentiation associated gene (mda-7) into the cell under conditions that permit the expression of the gene so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a method for reversing the cancerous phenotype of a cancer cell by introducing the gene product of the above-described gene into the cancerous cell so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a pharmaceutical composition having an amount of a nucleic acid having the melanoma differentiation associated gene (mda-7) or the gene product of a melanoma differentiation associated gene (mda-7) effective to reverse the cancerous phenotype of a cancer cell and a pharmaceutically acceptable carrier.

6413717, Jul 2, 2002

Mar 18, 1998

09/040981

Yilong Sun - Fort Lee NJ
Paul B. Fisher - Scarsdale NY
Neil I. Goldstein - Maplewood NJ

Corixa Corporation - Seattle WA

C12Q 168

435 6, 435 912

Methods are provided for identifying agents that modulate the expression of genes, such as genes encoding tumor suppressor or tumor-promoting proteins. The methods generally comprise screening candidate agents for the ability to enhance expression of a tumor suppressor gene, such as mda-7, or for the ability to inhibit expression of a tumor-promoting gene within a cell. Modulating agents may be used, for example, within anti-cancer therapies.

6440741, Aug 27, 2002

Mar 15, 1999

09/268303

Paul B. Fisher - Scarsdale NY
Rahul Gopalkrishnan - New York NY

The Trustees of Columbia University in the City of New York - New York NY

C12N 1500

435455, 4353201, 435325, 435 691

A vector having the Protein Translation Peptide Elongation Factor-1 (EF-1) promoter and nucleic acids encoding a reverse tetracycline-controlled activator is provided, wherein the expression of the activator is under the control of the EF-1 promoter. In addition, a method of generating a reverse tetracycline-controlled transactivator expression system for inducible tetracycline-regulated gene expression is provided that consists of: (a) isolation of a DNA fragment encoding the reverse tetracycline-controlled transactivator, (b) isolation of a DNA fragment containing the EF-1 promoter, (c) subcloning of these DNA fragments into a plasmid or other suitable vector to create a vector in which the reverse tetracycline-controlled transactivator is operably linked to the EF-1 promoter.

6472520, Oct 29, 2002

Mar 31, 1998

09/052753

Paul B. Fisher - Scarsdale NY

The Trustees of Columbia University in the City of New York - New York NY

C07H 2104

536 241, 536 231, 4353201

This invention provides a vector suitable for introduction into a cell, having: a) an inducible PEG-3 regulatory region; and b) a gene encoding a product that causes or may be induced to cause the death or inhibition of cancer cell growth. In addition, this invention further provides the above-described vectors, wherein the inducible PEG-3 regulatory region is a promoter. This invention further provides the above-described vectors, wherein the gene encodes an inducer of apoptosis. In addition, this invention provides the above-described vectors, wherein the gene is a tumor suppressor gene. In addition, this invention provides the above-described vectors, wherein the gene encodes a viral replication protein. This invention also provides the above-described vectors, wherein the gene encodes a product toxic to cells or an intermediate to a product toxic to cells. In addition, this invention provides the above-described vectors, wherein the gene encodes a product causing enhanced immune recognition of the cell.

6548650, Apr 15, 2003

Jun 30, 1999

09/345883

Paul B. Fisher - Scarsdale NY

Trustees of Columbia University in the City of New York - New York NY

C07H 2104

536 221, 435 6, 435 72, 435 723, 436 63, 436 64, 530300

This invention provides a method for producing a temporally paced subtracted cDNA library comprising: a) isolating temporally spaced RNAs from cells; b) generating cDNA inserts from the RNAs isolated from step (a); c) producing a temporally spaced cDNA library having clones containing the cDNA inserts generated from step (b); d) producing double stranded cDNA inserts from the temporally spaced cDNA library; e) denaturing the double stranded cDNA inserts; f)contacting the denatured double stranded cDNA inserts produced in step (e) with single-stranded DNAs from another cDNA library under conditions permitting hybridization of the single-stranded DNAs and the double-stranded cDNA inserts; g) separating the hybridized cDNA inserts from the unhybridized inserts; h) generating a cDNA library of the unhybridized inserts, thereby generating a temporally spaced subtracted cDNA library.

6657053, Dec 2, 2003

Aug 23, 2000

09/644460

Paul B. Fisher - Scarsdale NY

The Trustees of Columbia University in the City of New York - New York NY

C12N 1512

536 231, 536 235

This invention provides a method for identifying differentially expressed nucleic acids between two samples, comprising: a) selecting a first and second nucleic acid sample; b) producing libraries for the first and second nucleic acid sample; c) performing reciprocal subtraction between the libraries to produce two subtracted libraries; d) amplifying the two subtracted libraries; and e) comparing the two amplified subtracted libraries to identify differentially expressed nucleic acids. Also, this invention provides the above-described method, wherein the 3â primer used in the PCR amplification is an oligo dT 3â primer. This invention also provides the above-described methods, wherein the comparing of step e comprises using a gel to separate the nucleic acids from both of the libraries. This invention provides the isolated nucleic acid identified by the the above-described methods, wherein the nucleic was not previously known to be differentially expressed between the two samples.

6677152, Jan 13, 2004

Mar 5, 1999

09/263178

Paul B. Fisher - Scarsdale NY

The Trustees of Columbia University in the City of New York - New York NY

C12N 1563

4353201, 536 245, 435325

This invention provides a method for reversing cancer phenotype of a cancer cell by introducing an exogenous material which is capable of specifically recognizing either a Prostrate Tumor Inducing Gene, RNA or gene product of the aforementioned gene into the cell under conditions permitting inhibition of the expression of the gene product so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a method for reversing cancer phenotype of a cancer cell in a subject by introducing an exogenous material which is capable of specifically recognizing a Prostrate Tumor Inducing Gene, RNA or gene product of the aforementioned gene into the subjects cancer cell under conditions permitting inhibition of the expression of the gene or function of the gene product in the subjects cell so as to thereby reverse the cancerous phenotype of the cell.

6720408, Apr 13, 2004

Dec 23, 1998

09/221268

Paul B. Fisher - Scarsdale NY
Hongping Jiang - New York NY

The Trustees of Columbia University in the City of New York - New York NY

C07H 2100

536 231, 435 6, 435 691, 435325, 536 241, 536 243, 536 2431, 536 2432, 536 2433

This invention provides a method of generating a subtracted cDNA library of a cell comprising: a) generating a cDNA library of the cell; b) isolating double-stranded DNAs from the cDNA library; c) releasing the double-stranded cDNA inserts from the double-stranded DNAs; d) denaturing the isolated double-stranded cDNA inserts; e) hybridizing the denatured double-stranded cDNA inserts with a labelled single-stranded nucleic acid molecules which are to be subtracted from the cDNA library; and f) separating the hybridized labeled single-stranded nucleic acid molecule from the double-stranded cDNA inserts, thereby generating a subtracted cDNA library of a cell. This invention also provides different uses of the subtracted library.